Under the agreement, multi-disciplinary teams from both the parties are expected to collaborate to jointly identify and validate new targets for drug discovery.
Sanford-Burnham has provided exclusive rights to OMJPI to access a multi-disciplinary team of scientists and a translational infrastructure dedicated to find new approaches to treat patients with neurological and psychiatric conditions for three years.
Sanford-Burnham is entitled to receive an upfront and yearly access payment, funding of discovery research in the field, milestone payments and royalties for successfully developed products.
Sanford-Burnham Drug Discovery and Development vice president Michael Jackson said this agreement sets the stage for Sanford-Burnham to fully leverage the drug discovery infrastructure the Institute has put into place over the last five years.